Role of emerging campylobacter species in inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 2189-2197

  Kaakoush, Nadeem O ^a   Mitchell, Hazel M ^a   Man, Si Ming ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Bacteria; Campylobacter; Crohn's disease; Etiology; Inflammatory bowel diseases; Microbiota; Pathogens; Ulcerative colitis

Indexed keywords

TOXIN;

AUTOPHAGY; CAMPYLOBACTER; CAMPYLOBACTER CONCISUS; CAMPYLOBACTER CURVUS; CAMPYLOBACTER GRACILIS; CAMPYLOBACTER LARI; CROHN DISEASE; DISEASE ASSOCIATION; FLAGELLUM; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PATHOTYPE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; CAMPYLOBACTERIOSIS; COMPLICATION; INFLAMMATORY BOWEL DISEASES; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOGENICITY; PROGNOSIS;

CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

EID: 84921407965     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000074     Document Type: Review

References (67)

1. Long MD, Hutfless S, Kappelman MD, et al. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2014;20:398-415.
2. Man SM, Kaakoush NO, Mitchell HM. The role of bacteria and patternrecognition receptors in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2011;8:152-168.
3. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
4. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620-1633.
5. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66: 5224-5231.
6. Lepage P, Hasler R, Spehlmann ME, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141:227-236.
7. Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599-608.
8. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:968-984.
9. Mukhopadhya I, Hansen R, El-Omar EM, et al. IBD-what role do proteobacteria play? Nat Rev Gastroenterol Hepatol. 2012;9:219-230.
10. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2012;9:88-96.
11. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37:42-47.
12. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1:164.
13. Gordon H, Harbord M. A patient with severe Crohn's colitis responds to faecal microbiota transplantation. J Crohns Colitis. 2014;8:256-257.
14. Zhang FM, Wang HG, Wang M, et al. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. World J Gastroenterol. 2013;19:7213-7216.
15. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:503-516.
16. Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108:1620-1630.
17. Kahn SA, Vachon A, Rodriquez D, et al. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013;19:1506-1513.
18. Kump PK, Grochenig HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013;19:2155-2165.
19. Bloom SM, Bijanki VN, Nava GM, et al. Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe. 2011;9:390-403.
20. Strauss J, Kaplan GG, Beck PL, et al. Invasive potential of gut mucosaderived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17:1971-1978.
21. Man SM. The clinical importance of emerging Campylobacter species. Nat Rev Gastroenterol Hepatol. 2011;8:669-685.
22. Kaakoush NO, Mitchell HM. Campylobacter concisus: a new player in intestinal disease. Front Cell Infect Microbiol. 2012;2:4.
23. Kaakoush NO, Man SM, Mitchell HM. Functional relationship between campylobacter concisus and the stomach ecosystem in health and disease. ISME J. 2013;7:2245-2247.
24. von Rosenvinge EC, Song Y, White JR, et al. Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. ISME J. 2013;7:1354-1366.
25. Nielsen HL, Engberg J, Ejlertsen T, et al. Psychometric scores and persistence of irritable bowel after Campylobacter concisus infection. Scand J Gastroenterol. 2014;49:545-551.
26. Nielsen HL, Ejlertsen T, Engberg J, et al. High incidence of Campylobacter concisus in gastroenteritis in North Jutland, Denmark: a population-based study. Clin Microbiol Infect. 2013;19:445-450.
27. Hess DL, Pettersson AM, Rijnsburger MC, et al. Gastroenteritis caused by Campylobacter concisus. J Med Microbiol. 2012;61:746-749.
28. Moore JE, Barton MD, Blair IS, et al. The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect. 2006;8:1955-1966.
29. Aabenhus R, Permin H, On SL, et al. Prevalence of Campylobacter concisus in diarrhoea of immunocompromised patients. Scand J Infect Dis. 2002;34:248-252.
30. Zhang L, Man SM, Day AS, et al. Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease. J Clin Microbiol. 2009;47:453-455.
31. Man SM, Zhang L, Day AS, et al. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease. Inflamm Bowel Dis. 2010;16:1008-1016.
32. Kaakoush NO, Day AS, Huinao KD, et al. Microbial dysbiosis in pediatric patients with Crohn's disease. J Clin Microbiol. 2012;50:3258-3266.
33. Mahendran V, Riordan SM, Grimm MC, et al. Prevalence of Campylobacter species in adult Crohn's disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS One. 2011; 6:e25417.
34. O'Brien CL, Pavli P, Gordon DM, et al. Detection of bacterial DNA in lymph nodes of Crohn's disease patients using high throughput sequencing. Gut. [published online January 5, 2014]. doi: 10.1136/gutjnl-2013-305320.
35. Tankovic J, Burghoffer B, Petit JC. Frequent detection by real-time PCR of bacteria from the helicobacter and campylobacter genera in stool samples from inflammatory bowel disease patients. Eur J Clin Microbiol Infect Dis. Abstract presented at: 19th European Congress of Clinical Microbiology and Infectious Diseases Helsinki, Finland, 16-19 May 2009.
36. Hansen R, Berry SH, Mukhopadhya I, et al. The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: the BISCUIT Study. PLoS One. 2013;8:e58825.
37. Kaakoush NO, Castano-Rodriguez N, Day AS, et al. Campylobacter concisus and exotoxin 9 levels in paediatric patients with Crohn's disease and their association with the intestinal microbiota. J Med Microbiol. 2014;63:99-105.
38. Deshpande NP, Kaakoush NO, Wilkins MR, et al. Comparative genomics of Campylobacter concisus isolates reveals genetic diversity and provides insights into disease association. BMC Genomics. 2013;14:585.
39. Kaakoush NO, Deshpande NP, Wilkins MR, et al. The pathogenic potential of Campylobacter concisus strains associated with chronic intestinal diseases. PLoS One. 2011;6:e29045.
40. Zhang L, Budiman V, Day AS, et al. Isolation and detection of Campylobacter concisus from saliva of healthy individuals and patients with inflammatory bowel disease. J Clin Microbiol. 2010;48:2965-2967.
41. Ismail Y, Mahendran V, Octavia S, et al. Investigation of the enteric pathogenic potential of oral Campylobacter concisus strains isolated from patients with inflammatory bowel disease. PLoS One. 2012;7:e38217.
42. Mukhopadhya I, Thomson JM, Hansen R, et al. Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS One. 2011;6:e21490.
43. Rajilic-Stojanovic M, Shanahan F, Guarner F, et al. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013;19:481-488.
44. Holmstrom K, Collins MD, Moller T, et al. Subdoligranulum variabile gen. nov., sp. nov. from human feces. Anaerobe. 2004;10:197-203.
45. Wright JA, Grant AJ, Hurd D, et al. Metabolite and transcriptome analysis of Campylobacter jejuni in vitro growth reveals a stationary-phase physiological switch. Microbiology. 2009;155:80-94.
46. Thomas MT, Shepherd M, Poole RK, et al. Two respiratory enzyme systems in Campylobacter jejuni NCTC 11168 contribute to growth on L-lactate. Environ Microbiol. 2011;13:48-61.
47. Masanta WO, Heimesaat MM, Bereswill S, et al. Modification of intestinal microbiota and its consequences for innate immune response in the pathogenesis of campylobacteriosis. Clin Dev Immunol. 2013; 2013:526860.
48. Bereswill S, Plickert R, Fischer A, et al. What you eat is what you get: novel Campylobacter models in the quadrangle relationship between nutrition, obesity, microbiota and susceptibility to infection. Eur J Microbiol Immunol (Bp). 2011;1:237-248.
49. Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10:168-174.
50. Man SM, Kaakoush NO, Leach ST, et al. Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Campylobacter jejuni Campylobacter species. J Infect Dis. 2010;202:1855-1865.
51. Lavrencic P, Kaakoush NO, Huinao KD, et al. Investigation of motility and biofilm formation by intestinal Campylobacter concisus strains. Gut Pathog. 2012;4:22.
52. Gunther NWt, Chen CY. The biofilm forming potential of bacterial species in the genus Campylobacter. Food Microbiol. 2009;26:44-51.
53. Rubinchik S, Seddon A, Karlyshev AV. Molecular mechanisms and biological role of Campylobacter jejuni attachment to host cells. Eur J Microbiol Immunol (Bp). 2012;2:32-40.
54. Kaakoush NO, Man SM, Lamb S, et al. The secretome of Campylobacter concisus. FEBS J. 2010;277:1606-1617.
55. Kaakoush NO, Mitchell HM, Man SM. Campylobacter. In: Tang YW, ed. Molecular Medical Microbiology. 2nd ed. London: Elsevier; 2014.
56. Nielsen HL, Nielsen H, Ejlertsen T, et al. Oral and fecal Campylobacter concisus strains perturb barrier function by apoptosis induction in HT-29/ B6 intestinal epithelial cells. PLoS One. 2011;6:e23858.
57. Deshpande NP, Kaakoush NO, Mitchell H, et al. Sequencing and validation of the genome of a Campylobacter concisus reveals intra-species diversity. PLoS One. 2011;6:e22170.
58. Burgos-Portugal JA, Mitchell HM, Castano Rodriguez N, et al. The role of autophagy in the intracellular survival of Campylobacter concisus. FEBS OpenBio. 2014;4:301-309.
59. McCarroll SA, Huett A, Kuballa P, et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet. 2008;40:1107-1112.
60. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39:596-604.
61. Zhang L, Lee H, Grimm MC, et al. Campylobacter concisus and inflammatory bowel disease. World J Gastroenterol. 2014;20:1259-1267.
62. Mahendran V, Tan YS, Riordan SM, et al. The prevalence and polymorphisms of zonula occluden toxin gene in multiple Campylobacter concisus strains isolated from saliva of patients with inflammatory bowel disease and controls. PLoS One. 2013;8:e75525.
63. Engberg J, Bang DD, Aabenhus R, et al. Campylobacter concisus: an evaluation of certain phenotypic and genotypic characteristics. Clin Microbiol Infect. 2005;11:288-295.
64. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology. 1998;115:1405-1413.
65. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004;127:412-421.
66. Kovach Z, Kaakoush NO, Lamb S, et al. Immunoreactive proteins of Campylobacter concisus, an emergent intestinal pathogen. FEMS Immunol Med Microbiol. 2011;63:387-396.
67. Ismail Y, Lee H, Riordan SM, et al. The effects of oral and enteric Campylobacter concisus strains on expression of TLR4, MD-2, TLR2, TLR5 and COX-2 in HT-29 cells. PLoS One. 2013;8:e56888.